Moreover, a Kaplan‐Meier survival analysis of the CNVs database containing 573 MM patients revealed that patients with NEK2 amplification had a significantly shorter overall survival (OS) (NEK2Amp group, median, 40 months) than the patients with a normal copy number (NEK2N group, median, 60 months, Figure 1C). The gene discussed is NEK2; the disease is Miyoshi myopathy.